From FDA labels and ClinicalTrials.gov

Do GLP-1s lower blood pressure?

Last updated

If your prescriber prescribes one: the lowest self-pay GLP-1 prices now

  • Lowest compounded tirzepatide on a monthly plan, not FDA-approved

    Collective

    $69/mo + $199/yr membership · about $86 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest compounded semaglutide on a monthly plan, not FDA-approved

    Collective

    $59/mo + $199/yr membership · about $76 a month over a year with the membership · first order: membership free for the first 21 days, never charged if you cancel before

  • Lowest FDA-approved, starting dose

    LillyDirect (Eli Lilly)

    from $149/mo

  • Lowest FDA-approved injection, starting dose

    NovoCare (Novo Nordisk)

    $199/fill initially

No current GLP-1 label lists high blood pressure as an approved use, so prescribing one for it would be off-label. Three STEP trials, pooled (Semaglutide 2.4 mg): Top blood pressure number fell 4.95 mmHg more than on placebo over 68 weeks, and much the same in people with high blood pressure (4.78 mmHg). The authors say weight loss explained much of it, and that part of the result may be because people cut back their blood pressure medicines. The trials were testing weight loss, not a treatment for high blood pressure. Eur Heart J, 2024 (pubmed.ncbi.nlm.nih.gov/39217502). ClinicalTrials.gov lists 30 trials of these medicines on it: 4 with posted results and 8 recruiting now.

Read from the registry and PubMed every day. The newest update here is Nov 18, 2026.

Published results

What the largest trials on high blood pressure found

Each read in the paper's abstract on Nov 6, 2026. Trials differ in who took part and how long they ran.

Three STEP trials, pooled

Semaglutide 2.4 mg · 3,136 people · Better than the comparison · Meta-analysis

Top blood pressure number fell 4.95 mmHg more than on placebo over 68 weeks, and much the same in people with high blood pressure (4.78 mmHg). The authors say weight loss explained much of it, and that part of the result may be because people cut back their blood pressure medicines. The trials were testing weight loss, not a treatment for high blood pressure.

Eur Heart J, 2024 (pubmed.ncbi.nlm.nih.gov/39217502)

The registry

Trials on high blood pressure, by medicine

A trial counts when the registry's conditions or title name this, and some study a related question, such as insulin sensitivity in people with the condition. A registered trial shows a question being asked, not that the answer is yes.

MedicineTrialsPosted resultsRecruiting
Semaglutide904
Liraglutide510
Tirzepatide502
Orforglipron401
Dulaglutide320
Exenatide210
Mazdutide201
Posted results

What trials on high blood pressure reported

Latest phases and largest trials first. Each result is the first primary outcome as its sponsor posted it to the registry, which is not peer review.

TrialMedicinePhasePeopleResult
IIH EVOLVEA Trial to Determine the Efficacy and Safety of Presendin in IIHExenatidePhase 314On ClinicalTrials.gov (clinicaltrials.gov)
NCT02299388To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot StudyLiraglutidePhase 411Change in Systolic Blood Pressure as Measured by Ambulatory Blood Pressure Monitors. (mm/Hg), Baseline and 8 Weeks. Liraglutide: -4.88; Placebo: -5.45.
NCT01149421A Study of the Effect of LY2189265 on Blood Pressure and Heart Rate in Type 2 DiabetesDulaglutidePhase 2755Change From Baseline to 16 Weeks in Mean 24-hour Systolic Blood Pressure (SBP) (millimeters of mercury (mmHg)), Baseline, 16 weeks. 1.5 Milligram (mg) LY2189265: -3.41; 0.75 Milligram (mg) LY2189265: -1.70; Placebo: -0.63.
NCT01324388A Study of the Effect of LY2189265 on Two Blood Pressure DrugsDulaglutidePhase 151Pharmacokinetics, Area Under the Concentration Curve (AUC) of Lisinopril ((nanograms*hours/milliliter)/milligram), Day -1, Day 3, Day 24 of Part 1, Day -1 (Baseline). Part 1: LY2189265 + Lisinopril: 1580; Part 1: Placebo + Lisinopril: 1740.
Recruiting now

Trials on high blood pressure taking people now

The registry page names each site and who can enroll. Ask your clinician before joining one.

TrialMedicinePhaseExpected to finish
A Study of Orforglipron in Participants With Overweight at Risk of Development of Obesity-Related Complications or Progression to Class 1 Obesity (clinicaltrials.gov/study/NCT07794579)OrforglipronPhase 3Sep 2030
Efficacy and Safety of IBI362 in Hypertensive Patients With Overweight/Obesity (clinicaltrials.gov/study/NCT07469800)MazdutidePhase 3Apr 15, 2027
Impact of Semaglutide Withdrawal on Cardiometabolic Profile and Physiology of Energy Balance: Recovery Effects After Semaglutide Termination (clinicaltrials.gov/study/NCT07294950)SemaglutidePhase 3May 2029
Impact GLP-1 Agonists Following Bariatric (clinicaltrials.gov/study/NCT06132477)SemaglutidePhase 4Jul 2030
Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease (clinicaltrials.gov/study/NCT07058155)SemaglutidePhase 4Feb 1, 2034
Tirzepatide in Idiopathic Intracranial Hypertension Trial (clinicaltrials.gov/study/NCT07191873)TirzepatidePhase 4Aug 2028
Feasibility of Semaglutide in Advanced Lung Disease (clinicaltrials.gov/study/NCT05746039)SemaglutidePhase 1/2Dec 28, 2027
A Trial Within Cohort Feasibility Study Design Comparing Standard of Care Versus Weight Loss (Achieved Through Tirzepatide) for Obesity-related Hypertension in Young Adults (clinicaltrials.gov/study/NCT07364175)TirzepatideNot phasedJan 2029
From PubMed

Newest papers on GLP-1s and high blood pressure

  • The effect of subcutaneous semaglutide injection on blood pressure: a systematic review and meta-analysis of randomized controlled trials (pubmed.ncbi.nlm.nih.gov/42987980)

    Meta-analysis · Diabetes Res Clin Pract · Nov 5, 2026 · Ahmadi N et al.

  • Weight loss and blood pressure lowering with GLP-1 receptor agonists and multi-hormone receptor modulators in overweight and obesity: a systematic review and meta-regression of phase 3 clinical trials (pubmed.ncbi.nlm.nih.gov/42903654)

    Systematic review · EClinicalMedicine · Oct 12, 2026 · Nardone M et al.

  • Glucagon-like peptide-1 receptor agonists in idiopathic intracranial hypertension: A systematic review and meta-analysis (pubmed.ncbi.nlm.nih.gov/42619634)

    Meta-analysis · Headache · Aug 20, 2026 · Falcão L et al.

  • Effect of tirzepatide and semaglutide on blood pressure: A systematic review and meta-analysis (pubmed.ncbi.nlm.nih.gov/42603240)

    Meta-analysis · Endocrine · Aug 15, 2026 · Chen QX et al.

  • Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis (pubmed.ncbi.nlm.nih.gov/42340790)

    Meta-analysis · Clin Ter · Jul 1, 2026 · Elganyny MKE et al.

  • Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials (pubmed.ncbi.nlm.nih.gov/42371360)

    Meta-analysis · High Blood Press Cardiovasc Prev · Jun 29, 2026 · Simental-Mendía LE et al.

Listed from Europe PMC as published, newest first. A listing here is not a judgement of a study's quality or a recommendation.

Updated automatically

What changed in trials on high blood pressure

  • TrialNew Tirzepatide study registered: Tirzepatide for the REduction of AceTazolamide in Idiopathic Intracranial Hypertension (clinicaltrials.gov/study/NCT07946315)
  • TrialNew Semaglutide study registered: A Research Study to Investigate How Well the Medicine CagriSema Lowers High Blood Pressure in People Living With High Blood Pressure and Obesity (clinicaltrials.gov/study/NCT07919405)

Written from each source's own record as it changes. Every change on GLPcompare

Questions

GLP-1s and high blood pressure: common questions

What did the largest trial on high blood pressure find?

Three STEP trials, pooled (Semaglutide 2.4 mg, 3,136 people): Top blood pressure number fell 4.95 mmHg more than on placebo over 68 weeks, and much the same in people with high blood pressure (4.78 mmHg). The authors say weight loss explained much of it, and that part of the result may be because people cut back their blood pressure medicines. The trials were testing weight loss, not a treatment for high blood pressure.

Is any GLP-1 FDA approved for high blood pressure?

Not in any current label we read. A prescriber can still use a medicine off-label, but insurance often limits coverage to approved uses, so ask your plan.

Which GLP-1 has been studied most for high blood pressure?

Semaglutide, with 9 registered trials on it, then Liraglutide and Tirzepatide with 5 each. More trials do not mean better results: read what each posted.

Can I join a trial of a GLP-1 for high blood pressure?

8 trials are recruiting on ClinicalTrials.gov now, listed on this page with their registry pages, which name each site and who can enroll.

Other conditions

GLPcompare is an informational data platform, not a medical provider or pharmacy. Nothing here is medical advice, a diagnosis, or a recommendation to start, stop, or change any treatment. Data is aggregated from public sources and can be incomplete or out of date. Always confirm with a licensed clinician and the current FDA label.